Handa, Intas Face Patent Suits Over Exelixis Cancer Drug
By Adam Lidgett · July 8, 2026, 2:48 PM EDT
Handa Pharmaceuticals and Intas Pharmaceuticals are wrongly trying to bring to market drugs that would compete with Exelixis Inc.'s blockbuster cancer pill Cabometyx before patents on the medication expire, according to...
To view the full article, register now.